Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P21554 (
cannabinoid receptor
)
3,582
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Using a yeast two-hybrid screen, the neuronal membrane glycoprotein
M6a
, a member of the proteolipid protein family, was identified to be associated with the mu-opioid receptor (MOPr). Bioluminescence resonance energy transfer and co-immunoprecipitation experiments confirmed that
M6a
interacts agonist-independently with MOPr in human embryonic kidney 293 cells co-expressing MOPr and
M6a
. Co-expression of MOPr with
M6a
, but not with M6b or DM20, exists in many brain regions, further supporting a specific interaction between MOPr and
M6a
. After opioid treatment
M6a
co-internalizes and then co-recycles with MOPr to cell surface in transfected human embryonic kidney 293 cells. Moreover, the interaction of
M6a
and MOPr augments constitutive and agonist-dependent internalization as well as the recycling rate of mu-opioid receptors. On the other hand, overexpression of a
M6a
-negative mutant prevents mu-opioid receptor endocytosis, demonstrating an essential role of
M6a
in receptor internalization. In addition, we demonstrated the interaction of
M6a
with a number of other G protein-coupled receptors (GPCRs) such as the delta-opioid receptor,
cannabinoid receptor CB1
, and somatostatin receptor sst2A, suggesting that
M6a
might play a general role in the regulation of certain GPCRs. Taken together, these data provide evidence that
M6a
may act as a scaffolding molecule in the regulation of GPCR endocytosis and intracellular trafficking.
...
PMID:Membrane glycoprotein M6a interacts with the micro-opioid receptor and facilitates receptor endocytosis and recycling. 1754 56